Effects of prolonged cold storage on purinergic and adrenergic components of sympathetic co-transmission in isolated canine splenic arteries.
The present study demonstrated the progressive inhibition by prolonged cold storage (4, 7 and 14 days at 4 degrees C) on prejunctional and postjunctional functions of purinergic and adrenergic components of double-peaked vasoconstrictor responses to periarterial electrical nerve stimulation in the isolated canine splenic artery. After the cold storage for 4 days, the first phase constriction was markedly decreased, whereas the second response was not significantly modified. Furthermore, after the 7 days of cold storage, the first phase was substantially depressed at low frequencies, but at high frequencies, a low level of contractile responses was still observed. On the other hand, the second phase in the cold stored artery for 7 days largely remained at any used frequencies. Moreover, the 14 days of cold storage almost completely inhibited the vasoconstrictor responses to nerve stimulation. Tyramine-induced constrictions were progressively decreased in the stored-days dependent manner, although the ATP and the noradrenaline-induced one was not modified for 4 and 7 days of the cold storage. In conclusion, 1) the 4 degrees C cold stored artery for 4 days may show preferential injury of its tyramine-dependent noradrenaline releasing mechanisms, whereas nerve excited ones might well remain; and 2) the prejunctional contractile response of purinergic transmission might be damaged more preferentially than that of adrenergic transmission within 7 days storage.
Yang
X P
XP
Department of Pharmacology, Shinshu University School of Medicine, Matsumoto, Japan.
Chiba
S
S
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000494:pharmacology; D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D003080:Cold Temperature; D004285:Dogs; D004558:Electric Stimulation; D005260:Female; D066298:In Vitro Techniques; D008297:Male; D009131:Muscle, Smooth, Vascular / Q000294:innervation* / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D011224:Prazosin / Q000494:pharmacology; D058913:Purinergic Agonists; D058914:Purinergic Antagonists; D018340:Receptors, Adrenergic, alpha-1 / Q000187:drug effects; D011983:Receptors, Purinergic / Q000502:physiology*; D013157:Splenic Artery / Q000294:innervation* / Q000502:physiology; D013564:Sympathetic Nervous System / Q000502:physiology*; D009435:Synaptic Transmission / Q000502:physiology*; D013997:Time Factors; D014021:Tissue Preservation; D014439:Tyramine / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D058913:Purinergic Agonists; D058914:Purinergic Antagonists; D018340:Receptors, Adrenergic, alpha-1; D011983:Receptors, Purinergic; D000255:Adenosine Triphosphate; C002630:alpha,beta-methyleneadenosine 5'-triphosphate; D009638:Norepinephrine; D014439:Tyramine; D011224:Prazosin